Saeed Salehin Akhand

Saeed Salehin Akhand

Auto-generated profile, based on publicly available information

Saeed Salehin Akhand

Precision Medicine Oncology, AbbVie Bay Area, South San Francisco, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Cancer Research
Verified
Journal Article
Closed access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
NK cell–redirecting therapies are emerging as promising “off the shelf” cancer treatments with fewer safety issues compared with T cell–directed therapies. In this study, we developed ABBV-303, a c-Met–targeted multispecific NK-cell engager. ABBV-303 included three functional arms: (i) a c-Met–binding single-chain variable fragment; (ii) a Fab that binds NKG2D, a stimulatory receptor on NK cells, and activated CD8+ T cells; and (iii) a heterodimeric IgG1 Fc that binds FcγRIIIa on NK cells. ABBV-303 binding to NKG2D and FcγRIIIa redirected NK cells to lyse c-Met–expressing tumor cells and induced CD8+ T-cell activation. The treatment of peripheral blood mononuclear cells with ABBV-303 in the presence of c-Met+ tumor cells stimulated NK and CD8+ T cells as demonstrated by modulation of activation-associated surface proteins and release of soluble factors. ABBV-303 drove subnanomolar redirected killing potency against tumor cells from different solid tumor indications expressing a range of c-Met levels. ABBV-303 demonstrated antitumor activity against established xenografts in CD34-humanized, IL15 transgenic NOD/SCID-gamma mice and in a c-Met+ tumor explant. When compared with a CD3 bispecific with the same c-Met binder, ABBV-303 drove lower levels of inflammatory cytokines at equivalent levels of tumor cell killing and enhanced tolerance of normal cells expressing c-Met, consistent with the natural tendency of NK cells to preferentially react with stressed or cancer cells as compared with normal, healthy tissue. Together, this study showed that ABBV-303 is effective at driving antitumor immunity against a wide range of c-Met–expressing tumors. Significance: ABBV-303 is a biologic that engages and potently redirects NK cells and costimulates CD8+ T cells in c-Met expressing tumors while demonstrating relative tolerance of normal tissue-derived cells.

19 October 2025 in bioRxiv
Verified
Preprint
Open access
ADAlisha Dhiman
Alisha Dhiman
MAMitchell G. Ayers
Mitchell G. Ayers
JMJamie L. McCuiston
Jamie L. McCuiston
ASAparna Shinde
Aparna Shinde
SASaeed Salehin Akhand
Saeed Salehin Akhand
EDEmily Dykhuizen
Emily Dykhuizen
SWI/SNF chromatin remodelers utilize ATP to mobilize nucleosomes on DNA and are represented by three biochemically distinct subcomplexes, the more abundant cBAF and the less abundant PBAF and GBAF subcomplexes. Patient mutations and genetic studies have identified important roles for PBAF subunits in development and disease; however, relating PBAF-mediated phenotypes to biochemical function in chromatin regulation and gene expression has been challenging. Further complicating matters, cell-based systems often do not reflect the phenotypes and genotypes observed with PBAF mutations in vivo . Here we show that the PBRM1 subunit of PBAF is critical for the completion of TGFB1-mediated epithelial-mesenchymal transition of mammary cells in vitro as well as the metastasis of murine breast cancers in vivo. Using epigenomics to profile different stages of EMT, we find that PBRM1 is necessary for targeting PBAF to inducible promoters marked by H3K14ac alone. We further find that PBRM1 facilitates DNA accessibility at sites bound by TGFβ1-inducible transcription factors, such as Atf3, for the induction of genes involved in migration, cell survival, and inflammation. Our model allows us to separate constitutive vs inducible gene expression to help explain some of the context-dependent phenotypes observed with PBRM1 deletion. In addition, we provide evidence that while PBRM1 deletions can promote the initiation of certain cancers in early stages, PBAF may be a vulnerability in late-stage metastatic cancers.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
Gating strategy to analyze cell types and response to ABBV-303 in fresh human tumor explant.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
Cancer cell lines, sources, and growth media

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
NK cells and CD8 T cells are not depleted when treated with ABBV-303.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
NK cell–redirecting therapies are emerging as promising “off the shelf” cancer treatments with fewer safety issues compared with T cell–directed therapies. In this study, we developed ABBV-303, a c-Met–targeted multispecific NK-cell engager. ABBV-303 included three functional arms: (i) a c-Met–binding single-chain variable fragment; (ii) a Fab that binds NKG2D, a stimulatory receptor on NK cells, and activated CD8+ T cells; and (iii) a heterodimeric IgG1 Fc that binds FcγRIIIa on NK cells. ABBV-303 binding to NKG2D and FcγRIIIa redirected NK cells to lyse c-Met–expressing tumor cells and induced CD8+ T-cell activation. The treatment of peripheral blood mononuclear cells with ABBV-303 in the presence of c-Met+ tumor cells stimulated NK and CD8+ T cells as demonstrated by modulation of activation-associated surface proteins and release of soluble factors. ABBV-303 drove subnanomolar redirected killing potency against tumor cells from different solid tumor indications expressing a range of c-Met levels. ABBV-303 demonstrated antitumor activity against established xenografts in CD34-humanized, IL15 transgenic NOD/SCID-gamma mice and in a c-Met+ tumor explant. When compared with a CD3 bispecific with the same c-Met binder, ABBV-303 drove lower levels of inflammatory cytokines at equivalent levels of tumor cell killing and enhanced tolerance of normal cells expressing c-Met, consistent with the natural tendency of NK cells to preferentially react with stressed or cancer cells as compared with normal, healthy tissue. Together, this study showed that ABBV-303 is effective at driving antitumor immunity against a wide range of c-Met–expressing tumors.Significance:ABBV-303 is a biologic that engages and potently redirects NK cells and costimulates CD8+ T cells in c-Met expressing tumors while demonstrating relative tolerance of normal tissue-derived cells.